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Abstract
Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer related mortality, any improvements in 
therapeutic strategies are urgently required. In this study we generated a novel 'suicide gene' armed oncolytic 
adenoviral vector and investigated its antitumor effect both in vitro and in vivo.
Methods: Since the up-regulated expression of human telomerase reverse transcriptase (hTERT) is a hallmark of 
alltypes of NSCLC, we chose hTERT promoter to transcriptionally control E1A gene expression to obtain adenoviral 
replication in NSCLC. In order to further enhance anti-tumor effect of this oncolytic adenoviral vector, we inserted a 
'suicide gene' i.e. Herpes Simplex Virus Thymidine Kinase (HSV-TK) into oncolytic adenoviral vector to engineer a novel 
armed oncolytic adenoviral vector 'Ad.hTERT-E1A-TK'.
Results: Ad.hTERT-E1A-TK efficiently killed different types of tumor cells including two types of NSCLC cells in vitro, 
causing no damage to normal primary fibroblasts. Furthermore, Ad.hTERT-E1A-TK infection combined with 
administration of prodrug gancyclovir (GCV) resulted in more potent cytotoxicity on NSCLC cells, and synergistically 
suppressed human NSCLC tumor growth in nude mice.
Conclusion: The results from this study showed that Ad.hTERT-E1A-TK/GCV could be a potent but safe anti-tumor 
strategy for NSCLC biotherapy.
Background
Lung cancer is one of the most common malignant neo-
plasm diseases in which non-small cell lung cancer
(NSCLC) constitutes 80%-85% of all lung cancers [1]. Due
to the lack of early diagnostic methods, most of NSCLC
cases are diagnosed at the late phase and patients usually
lose the opportunity of surgical treatment. Despite the
fact that chemotherapy and radiotherapy provides many
options to treat NSCLC, a survival plateau has been
reached and its mortality is still in the first place in cancer
patients [2,3]. Therefore it is urgent to explore other
treatment strategies. Molecule targeting therapy repre-
sents a rapidly growing cancer treatment strategy and
several drugs have been proven effective in many preclin-
ical and clinical setting [4,5]. Suicide gene therapy pos-
sesses the advantage of molecule targeting strategies
because the suicide gene functions in the transformed
tumor cells and then selectively kills transformed tumor
cells and their surrounding cells via bystander effects. In
some extent, the suicide gene therapy could overcome the
systemic toxicity of conventional chemotherapy. Herpes
Simplex Virus Thymidine Kinase/gancyclovir (HSV-TK/
GCV) is one of the most frequently utilized forms of sui-
cide gene therapy. HSV-TK can catalyze GCV into mono-
phosphorylated GCV (GCV-MP) that will then be
converted into toxic gancyclovir triphosphate (GCV-TP)
by other cellular kinases and thereafter cause cell growth
inhibition or initiates cell death. According to previous
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[6].
How to efficiently and selectively deliver HSV-TK gene
into tumor cells? It has been reported that the non-repli-
cative adenoviruses were able to infect and mediated
gene transfer into NSCLC [7]. The replication-competent
adenoviruses, also called oncolytic adenoviruses, are
thereby a natural extension from the success of non-repli-
cative adenoviruses mediated gene delivery. The advan-
tage of using the replication-competent adenoviruses for
therapeutic gene delivery is that it can selectively repli-
cate and spread in malignant tumor tissues, and finally
lead to remarkably increased therapeutic gene expression
in tumor cells accompanying adenoviral replication and
spread. The current strategy to generate tumor-selective
replication-competent adenovirus is to replace the aden-
ovirus E1 gene promoter with other tumor or tissue-spe-
cific promoter [8,9]. Since human telomerase reverse
transcriptase (hTERT) is over-expressed in all types of
NSCLC, but is inactivated in normal cells [10], in the
present study, we chose the hTERT promoter to drive
adenoviral E1A gene expression and generated a tumor-
selective replication-competent adenoviral vector. In
order to further enhance therapeutic efficacy, we inserted
a constitutive expression HSV-TK gene into this vector to
develop a novel armed oncolytic adenovirus (Ad.hTERT-
E1A-TK). We subsequently evaluated whether
Ad.hTERT-E1A-TK could preferentially replicate in
NSCLC and HSV-TK/GCV system could effectively kill
NSCLC both in vitro and in vivo.
Materials and methods
Cells and cell culture
HEK293 (human embryonic kidney 293) cells were pur-
chased from Invitrogen (San Diego, CA, USA). NCIH460
(human large cell lung cancer), A549 (human lung adeno-
carcinoma), SW1990 (human pancreas cancer), Hela
(human cervical carcinoma), and SMMC-7721 (human
hepatoma) were obtained from the Cells Bank of the Chi-
nese Academy of Science (Shanghai, China). Primary
human dermal fibroblasts were provided by our labora-
tory, and which was derived from bioptic tissue for der-
matoplasty (a written informed consent was obtained
from patients). Cells were cultured in DMEM or RPMI
1640 medium supplemented with 10% fetal bovine serum
(FBS).All of the tumor cells had activated telomerase
activities, while primary human dermal fibroblasts
showed lower telomerase activity according to our previ-
ous study.
Adenoviral vectors
Ad.hTERT-E1A-TK is an oncolytic adenoviral vector that
is able to replicate in hTERT activated tumor cells and
carries a constitutive expression HSV-TK-HAtag cassette.
The construction of Ad.hTERT-E1A-TK has been
described previously [11]. Ad.GFP is a replication-defec-
tive Ad that lacks adenoviral E1A gene and expresses the
green fluorescent protein gene (GFP). Ad.null is also a
replication-defective Ad but expresses no extraneous
gene. The dl309 is a wild-type Ad that contains intact
adenoviral E1 gene. Ad.hTERT-E1A and Ad.hTERT-E1A-
CD had similar structure with Ad.hTERT-E1A-TK and
were used as positive control for oncolytic adenovirus.
The former contains no therapeutic gene while the later
has Escherichia colicytosine deaminase gene (E coli CD)
instead of Herpes Simplex Virus Thymidine Kinase
(HSV-TK). Purified, high titer viral stocks were generated
according to the protocol described by Huang et al [12].
The schematic diagram of Ad.hTERT-E1A-CD or
Ad.hTERT-E1A-TK was shown in Additional file 1.
Western blot analysis
The adenoviral HSV-TK and E1A expression was con-
firmed by Western blot as described below. The cells
were plated in 6-well plates and infected with the
Ad.hTERT-E1A-TK at a multiplicity of infection (MOI) of
10 plaque forming units (PFU) per cell. Cells were har-
vested and lysed 48 h later after infection in SDS sample
buffer (containing 10 mM β-mercaptoethanol, 100 mM
Tris-CL [pH 6.8], 2% SDS, and 0.1% bromophenol blue).
Protein samples were separated by 10% SDS polyacrylam-
ide gel and transferred to a polyvinylidene difluoride
membrane (Amersham, Buckinghamshire, UK). The
blots were probed with anti-HA (Sigma, St. Louis, MO,
USA) monoclonal antibody which detected HSV-TK and
anti-Ad2 E1A (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) polyclonal antibody, followed by a secondary
horseradish peroxidase-conjugated antibody. The anti-
gen-antibody complexes were visualized using the
enhanced chemiluminescence kit (Roche, New York, NY,
USA) as recommended by the manufacturer.
Cytopathic effect assays
The cytopathic effect (CPE) was determined by three dif-
ferent methods. At first, tumor cells such as NCIH460,
SW1990, SMMC-7721 and Hela were plated into 24-well
plates and either infected with different dose of
Ad.hTERT-E1A-TK, Ad.hTERT-E1A-CD, dl309, Ad.GFP
or treated with prodrug gancyclovir (GCV) or 5-fluoro-
cytosine (5-FC) or untreated on the next day respectively.
Five days later the plates were stained with crystal violet
and the remaining living cells were determined by inten-
sity of blue color. The 2nd method was Cell Counting Kit-8
assay (CCK-8, Dojindo Molecular Technologies Inc.,
Gaithersburg, MD, USA) which could quantitatively
determine living cells by measuring optic intensity. The
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plates were treated with 10 MOI of Ad.hTERT-E1A-TK,
Ad.hTERT-E1A-TK plus GCV or GCV alone. Five days
later the remaining living cells were determined by CCK-
8 assay. The cytopathic effect was also observed by
microscopy for morphologic changes. NCIH460 cells and
primary human fibroblasts were plated into 6-well plates
and infected with 10 MOI of Ad.hTERT-E1A-TK, dl309,
or Ad.GFP respectively on the next day. CPE was moni-
tored and photographed by light microscopy at the differ-
ent time points.
Viral replication
To determine viral progeny production, NCIH460 cells (4
× 105cells/well) and primary fibroblasts (4 × 105cells/well)
were plated into 6-well plates and infected with
Ad.hTERT-E1A-TK at 10 MOI for 4 h. The medium con-
taining extra virus was removed and the cells were
washed once with PBS and cultured with fresh mediun.
24 h and 5 days later after infection, the cells were col-
lected and lysed by three rounds of freezing and thawing,
and then centrifuged to collect the supernatant. The ade-
noviral particles in the infected tumor cells or fibroblasts
supernatant were determined by plaque assay in HEK293
cells.
Animal experiments
Specific pathogen-free male athymic BALB/c nude mice,
4-6 weeks old (20-30 g), were obtained from the Institute
of Animal Center (Chinese Academy of Sciences, Shang-
hai, China). Mice were housed five per cage and allowed
free access to food and water. All animal procedures were
performed according to principles of laboratory animal
care (NIH publication No. 85-23, revised 1985) and the
current Chinese regulations and standards on the use of
laboratory animals. For tumor cell implantation,
NCIH460 cells (5 × 106) were subcutaneously injected
into the right dorsal lumbar region in 100 μl of phosphate
buffered saline (PBS). When the tumors grew up to
approximately 100 mm3, the animals were randomly
divided into 4 groups i.e. Ad.null, Ad.hTERT-E1A-TK,
Ad.hTERT-E1A-TK plus GCV and PBS plus GCV, and
each group contained at least 7 animals. About 1 × 109
PFU of Ad.null orAd.hTERT-E1A-TK in 100 μl PBS or
100 μl PBS alone were injected into tumors respectively.
On the 3rd day post virus injection, GCV (100 mg/kg/
day) was intraperitoneally administered for 14 consecu-
tive days. The tumor growth was assessed by measuring
bi-dimensional diameters twice a week with calipers. The
tumor volumes (V) were calculated according to the for-
mula V = 1/2ab2 (a represents the largest diameter and b
represents the smallest diameter). All animals were killed
4 weeks later after treatment and then the tumors were
removed and weighed.
Histopathologic examination of tumors
The resected tumors were fixed with 10% formalin and
embedded in paraffin. The tumor sections were stained
with hematoxylin-eosin and evaluated by two individual
pathologists.
Statistical analysis
All numerical data were expressed as mean ± SD. A com-
parison of means among two or more groups was per-
formed using one-way analysis of variance or
nonparametric test, and further confirmed by post-hoc
analyses with S-N-K or Games-Howell test. All statistical
analyses were conducted using SPSS 11.5 software (SPSS,
Chicago, IL). Differences with p < 0.05 were considered as
significant.
Results and discussion
Tumor specific replication and killing effect of Ad.hTERT-
E1A-TK
In the present study we generated a novel oncolytic aden-
oviral vector, Ad. hTERT-E1A-TK, in which tumor selec-
tive replication was mediated by the hTERT promoter
and HSV-TK gene expression was controlled by CMV
promoter. Given Ad.hTERT-E1A-TK contained a suicide
gene HSV-TK, we first examined TK expression in
Ad.hTERT-E1A-TK infected cells by Western blot. Our
results showed that TK expression could be detected in
Ad.hTERT-E1A-TK-infected tumor cells but not in con-
trol cells (Additional file 2). We next examined
Ad.hTERT-E1A-TK/GCV induced cytopathic effect. As
shown as crystal violet staining in Fig. 1A and Additional
file 3, Ad.hTERT-E1A-TK/GCV was able to kill different
type of tumor cells including NCIH460, SW1990,
SMMC-7721 and Hela. Its tumor killing effect was com-
parable with other oncolytic adenoviral vector such as
Ad.hTERT-E1A-CD/5-FC, and even superior to
Ad.hTERT-E1A as well as wild type adenovirus dl309 in
most tested cell lines. Furthermore, Ad.hTERT-E1A-TK
killed tumor cell in dose dependent manner. Ad.hTERT-
E1A-TK induced tumor cell killing effect was further con-
firmed by CCK-8 assay. As shown in Fig. 1B, two NSCLC
cell lines, NCIH460 and A549, and one human cervical
carcinoma cell line Hela showed significant reduction in
surviving cells after Ad.hTERT-E1A-TK infection, and
GCV could further enhance Ad.hTERT-E1A-TK induced
tumor cell killing effect.
In order to demonstrate that Ad.hTERT-E1A-TK
induced tumor cell killing effect was tumor specific, we
compared the cytopathic effect between NCIH460 tumor
cells and primary fibroblasts after 10 MOI of Ad.GFP,
Ad.hTERT-E1A-TK or dl309 infection. The non-replica-
tive adenovirus Ad.GFP caused no CPE in either tumor
or normal cells, while wild type adenovirus dl309 caused
similar CPE in both tumor and normal cells. Interestingly,
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blasts but caused CPE in tumor cells which is similar with
that in dl309 infected tumor cells (Fig. 2A). In order to
confirm that Ad.hTERT-E1A-TK induced tumor specific
killing effect was associated with its tumor specific repli-
cation, we performed plaque assay to quantify viral prog-
eny production. As shown in Fig. 2B, Ad.hTERT-E1A-TK
progenies detected in NCIH460 cells were approximately
7000 times more than that detected in primary fibro-
blasts. In more detail, about 2 × 107 and 2 × 105 of plaques
were detected in supernatant from Ad.hTERT-E1A-TK
infected NCIH460 cells and primary fibroblasts at 24 h
after infection, whereas on day 5 the plaques were 7 ×
Figure 1 Tumor cell killing effect of Ad.hTERT-E1A-TK on NSCLC 
NCIH460 cells. A. Crystal violet staining of tumor cells after infec-
tion with different adenoviral vectors. NSCLC NCIH460 cells were 
plated into 24-well plates and treated with different doses of adenovi-
ral vectors or prodrug or untreated as indicated in figure. 5 days later 
the plates were stained with crystal violet. B. CCK-8 assay for surviv-
ing cells after infection with Ad.hTERT-E1A-TK. NSCLC NCIH460 
and A549 cells, and cervical carcinoma Hela cellswere plated into 96-
well plates and infected by 10 MOI of Ad.hTERT-E1A-TK with or without 
0.5 μg/ml GCV. 5 days later the surviving cells were quantified with 
CCK-8 assay and normalized by untreated cells.
Figure 2 Selective replication and oncolysis of Ad.hTERT-E1A-TK. 
A. Comparison of cytopathic effects between NSCLC NCIH460 
and primary fibroblasts. NSCLC NCIH460 and primary fibroblasts 
were plated into 6-well plates and infected with 10 MOI of Ad.hTERT-
E1A-TK, dl309 or Ad.GFP. 5 days later cytopathic effects were observed 
and photographed by light microscopy. B. The virus progeny pro-
duction in NCIH460 cells and primary fibroblasts. NCIH460 and pri-
mary fibroblasts were infected with 10 MOI of Ad.hTERT-E1A-TK for 4 h 
then washed once with PBS and then cultured with fresh medium. On 
24 h and day 5 post infection, the cells were harvested for plaque assay. 
The plaques on HEK293 cells were counted and plotted. C. Western 
blotting analysis of E1A gene expression. NCIH460 and SW1990 
Cells were infected with Ad-hTERT-E1A-TK at a MOI of 10. Cell lysates 
were harvested 48 h later, and immunobloted by anti E1A antibody. 
HEK293 cells which had been transfected with E1A were used as posi-
tive control, and uninfected NCIH460 cells were used as negative con-
trol.
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primary fibroblasts respectively. The plaques detected at
24 h post infection might derive from left vital adenovirus
in the infected cells, however, the plaques detected on day
5 faithfully reflected the differential replication between
tumor and normal cells.
The expression of E1A gene can also be regarded as an
indirect evidence for adenoviral replication, hence we
performed Western blot to detect E1A expression in
Ad.hTERT-E1A-TK infected NCIH460 cells and primary
fibroblasts. 48 h after infection E1A expression was only
detected in NCIH460 cells but not in primary fibroblasts
which supported Ad.hTERT-E1A-TK selective-replica-
tion in tumor cells (Fig. 2C).
GCV enhanced Ad.hTERT-E1A-TK tumor killing effect in 
vitro
The advantage of using suicide gene as therapeutic gene
is that it can convert non-toxic prodrug into toxic thera-
peutic agent. Since this converting process occurs in
tumor site, it will save normal tissues from potential dam-
age by systemic administration of toxic therapeutic agent.
Next we investigated whether GCV could enhance
Ad.hTERT-E1A-TK mediated tumor cell killing effect in
vitro. To do this, NCIH460 tumor cells were infected with
10 MOI of Ad.hTERT-E1A-TK and then exposed to dif-
ferent concentration of GCV for 5 days. According to our
previous data, 10 MOI of Ad.GFP infection resulted in
approximately 80% GFP positive expression cells in
NCIH460 that suggested NCIH460 cells could be effi-
ciently transduced by Ad, therefore, we applied 10 MOI
of Ad.hTERT-E1A-TK to NCIH460 cells. The cells,
infected by Ad.hTERT-E1A-TK alone for 5 days, showed
about 60% death while the addition of GCV resulted in
significantly more cell death. For example, about 85% or
95% cell death were observed when GCV was o.4 μg/ml
or 0.8 μg/ml respectively. Therefore, GCV synergistically-
enhanced Ad.hTERT-E1A-TK induced tumor cell killing
effect in dose-dependent manner (Fig. 3A).
Ad.hTERT-E1A-TK/GCV suppressed tumor growth in vivo
The therapeutic effect of Ad.hTERT-E1A-TK alone or in
combination with GCV was evaluated using human
NSCLC nude mice models. The mice models were estab-
lished by subcutaneous injection of NCIH460 cells.
When the tumors grew up to approximately 100 mm3,
about 1 × 109 PFU of Ad.null orAd.hTERT-E1A-TK in 100
μl PBS or 100 μl PBS alone was injected into tumors
respectively. On the 3rd day post virus injection, GCV
(100 mg/kg/day) was intraperitoneally administered for
14 consecutive days. The tumor growth was assessed by
measuring bi-dimensional diameters twice a week with
calipers. As shown in Fig. 3B, the tumors treated by
Ad.hTERT-E1A-TK alone or Ad.hTERT-E1A-TK plus
Figure 3 GCV enhanced inhibition on tumor growth in vitro and 
in vivo. A. GCV enhanced Ad.hTERT-E1A-TK tumor killing effect in 
vitro. NCIH460 tumor cells were infected with 10 MOI of Ad.hTERT-
E1A-TK and then exposed to different concentration of GCV for 5 days. 
The surviving cells were quantified with CCK-8 assay and plotted. B. 
Ad.hTERT-E1A-TK/GCV suppressed tumor growth in vivo. 
NCIH460 xenograft tumors in nude mice were treated by Ad.null, PBS 
plus GCV, Ad.hTERT-E1A-TK alone or Ad.hTERT-E1A-TK plus GCV. Tu-
mor sizes were measured twice a week using calipers and tumor vol-
umes were plotted. C. Tumor weight at the end of the study. On day 
28 post treatment, all animals were sacrificed and the tumors were re-
moved and weighted. The data represent the mean ± SD from at least 
7 animals per group.
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when compared with that treated with Ad.null or PBS
plus GCV. On 16th day, the differences became more sig-
nificant. At the end of observation, the average tumor
sizes were 2440.00 mm3, 2287.00 mm3, 1274.50 mm3 and
435.01 mm3 in group of Ad.null, PBS plus GCV,
Ad.hTERT-E1A-TK alone, and Ad.hTERT-E1A-TK plus
GCV, respectively. Since Ad.null and PBS plus GCV
showed no difference in tumor growth or tumor size (p >
0.05), we took both Ad.null and PBS plus GCV together
as control. The tumor growth curve and tumor size
between control and Ad.hTERT-E1A-TK or Ad.hTERT-
E1A-TK plus GCV was significantly different (p = 0.025
or p = 0.008) and by 54.39% and 74.34% reduction in
tumor weight in Ad.hTERT-E1A-TK or Ad.hTERT-E1A-
TK plus GCV treated groups compared with controls.
More importantly, the tumor growth curve and tumor
size between Ad.hTERT-E1A-TK and Ad.hTERT-E1A-TK
plus GCV also showed different (p = 0.040), it was about
43.75% reduction in tumor size in Ad.hTERT-E1A-TK
plus GCV treated group (Fig. 3C).
It is necessary to mention that the timing for prodrug
giving was on the 3rd day in this study. The reason was
mainly dependent on our previous study in which the
transgene expression reached the peak on the 3rd day after
intratumoral injection of either replication-competent or
replication-deficient adenoviral vectors. In that study the
transgene (red fluorescent protein, RFP) expression was
visualized by in vivo imaging (data not shown), it reached
the peak on the 3rd day which might reflect full replica-
tion and distribution of adenoviral vectors in tumor tis-
sue. Whether the advanced administration of GCV would
result in the suppression on adenoviral replication in
tumor tissues or interferer with therapeutic efficacy of
Ad.hTERT-E1A-TK has not been investigated in this
study.
The tumor sections from different groups also showed
differential histopathologic features. The most obvious
difference was the numbers of apoptotic cells and the
range of necrosis area. As shown in Fig. 4, tumors treated
with Ad.hTERT-E1A-TK plus GCV showed wider necro-
sis and more dark-stained and condensed nuclei.
Conclusion
Taking together, we have generated a novel oncolytic ade-
noviral vector in which the main difference with cur-
rently used oncolytic adenoviral vector ONYX-015 is
hTERT controlled replication and armed with HSV-TK.
The hTERT promoter used in this study is high strin-
gency and provide the base for tumor-specific replication.
Ad.hTERT-E1A-TK itself was able to inhibit tumor
growth thanks to its replicative ability and oncolytic
effect. Moreover, its tumor killing effect could be further
enhanced by prodrug GCV. Our study showed that
Ad.hTERT-E1A-TK/GCV could efficiently kill NSCLC
tumor cells both in vitro and in vivo. Therefore, we con-
cluded that Ad.hTERT-E1A-TK, as a potent and safe anti-




NSCLC: Non-small cell lung cancer; HSV: Herpes Simplex Virus; TK: Thymidine
Kinase; CGV: gancyclovir; hTERT: human telomerase reverse transcriptase; MOI:
multiplicity of infection; PFU: plaque forming units; CPE: cytopathic effect; CCK-
8: Cell Counting Kit-8.
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Additional file 1 Schematic diagram of Ad.hTERT-E1A-CD or 
Ad.hTERT-E1A-TK adenoviral construct. Ad.hTERT-E1A-CD or Ad.hTERT-
E1A-TK adenoviral vector had been constructed in the way described in this 
figure. ITR, inverted repeats of the adenovirus genome; ΔE1 and ΔE3, E1 and 
E3 region deleted.
Additional file 2 Western blotting analysis of TK gene expression. 
NCIH460 Cells were infected with Ad-hTERT-E1A-TK at a MOI of 10. Cell 
lysates were harvested 48 h later, and immunobloted by anti HA-tag anti-
body. NCIH460 Cells which had been transfected with plasmid containing 
TK gene were used as positive control, and uninfected NCIH460 cells were 
used as negative control.
Additional file 3 Tumor cell killing effect of Ad.hTERT-E1A-TK on dif-
ferent tumor cells. Crystal violet staining of tumor cells after infection with 
different adenoviral vectors. SW1990, SMMC-7721 and HeLa cells were 
plated into 24-well plates and treated with different dose of adenoviral vec-
tors or prodrug or untreated as indicated in figure. 5 days later the plates 
were stained with crystal violet.
Figure 4 Histological examinations of NCIH460 tumors treated 
by different conditions. The hematoxylin-eosin stain of NCIH460 tu-
mors treated by different conditions, PBS plus GCV treated (A); Ad.null 
treated (B); Ad.hTERT-E1A-TK alone treated (C). Ad.hTERT-E1A-TK plus 
GCV treated (D). The necrosis is barely seen in control groups (A and B), 
while there are obvious necrotic areas and numerous apoptotic bodies 
in the tumor tissues treated by Ad.hTERT-E1A-TK alone or Ad.hTERT-
E1A-TK plus GCV treated (C and D). Original magnification ×400.
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